Home
/India Proposes Streamlined Registration For Ethics Committees 2026 Amendment
Agile Regulatory Updates

India Proposes Streamlined Registration for Ethics Committees (2026 Amendment)

India has proposed a 2026 amendment to simplify and streamline the registration process for ethics committees, aiming to improve efficiency and compliance in clinical research oversight.

Sanskriti 12 Feb 2026 2 min

Get Free Consultation

Phone

Fast replies · No spam · Real experts

India Proposes Streamlined Registration for Ethics Committees (2026 Amendment)

regulatory-alert-ethics-committee-registration-rules-are-changing

The Ministry of Health and Family Welfare has issued a significant draft notification aimed at simplifying the administrative process for clinical trials in India. Released on February 2, 2026, this proposal seeks to amend the New Drugs and Clinical Trials (NDCT) Rules, 2019, specifically targeting the registration process for Ethics Committees.

Key Changes: Removing the "Provisional" Hurdle

The primary focus of the New Drugs and Clinical Trials (Amendment) Rules, 2026, is to eliminate the requirement for "provisional" certificates. Under the proposed changes:

  • Omission of Sub-rule (3): Rule 17, sub-rule (3) of the 2019 Rules—which previously handled provisional requirements—will be entirely removed.
  • Direct Final Registration: Rule 17, sub-rule (4) is being rewritten to fast-track the process. Upon receiving an application in Form CT-01, the designated authority will scrutinize the documents. If the requirements are met, the authority will grant final registration to the Ethics Committee in Form CT-03 immediately.
  • Accountability: If an application is rejected, the authority must record the specific reasons for doing so in writing.

Impact on Clinical Research

By removing the middle step of provisional registration, the government aims to reduce the "red tape" associated with setting up clinical trial oversight. This move is expected to speed up the commencement of clinical trials while maintaining strict adherence to safety and ethical standards.

Get Free Consultation!

Phone

Fast replies · No spam · Real experts

Call for Public Feedback

As this is a draft notification, the Central Government is actively seeking input from stakeholders and the public.

  • Timeline: Objections or suggestions must be submitted within thirty days from the date the Gazette copies were made available to the public.
  • Submission Details: Feedback should be addressed to the Under Secretary (Drugs), Ministry of Health and Family Welfare.
  • Contact: Correspondence can be sent to Room No. 434, C Wing, Nirman Bhavan, New Delhi, or via email at drugsdiv-mohfw@gov.in.

These rules will officially come into force on the date specified by the Government during their final publication in the Official Gazette.

Share 804 views

The Filing Process

The same four stages, every certificate

  1. 01

    Free Consultation

    We map your product or business against the regulators that apply to it, and flag what's realistic before any paperwork begins.

  2. 02

    Documentation

    Our advisors prepare and cross-check every form, test report and certificate the filing requires.

  3. 03

    Application Filing

    We submit through the correct portal or authority, and track the file until the regulator responds.

  4. 04

    Certificate Granted

    You receive the certificate or license, plus a renewal timeline so it never lapses unnoticed.